Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 9/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 9/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 9/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 9/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 9/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 9/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | IDE | P14735 | 1/20 | 0.61 |
| ▸ | MPI | P34949 | 1/20 | 0.61 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.61 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.61 |
| ▸ | S100A4 | P26447 | 1/20 | 0.56 |
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | DDO | Q99489 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8872873 | 0.90 | GRIN2D (0.82) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8873183 | 0.87 | GRIN2D (0.77) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL13295319 | 0.85 | GRIN2D (0.73) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8873922 | 0.84 | GRIN2D (0.72) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8895602 | 0.82 | GRIN2D (0.76) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7145476 | 0.80 | GRIN2D (0.67) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8895896 | 0.80 | GRIN2D (0.66) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL404811 | 0.78 | GRIN2D (0.79) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8896143 | 0.78 | GRIN2D (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8898790 | 0.78 | GRIN2D (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5622965-A | CENTRAL NERVOUS SYSTEM DISORDERS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-22 | — | — | US | claimed |
| EP-0688319-A4 | 4-HYDROXY-3-NITRO-1,2-DIHYDROQUINOLIN-2-ONES AND THE USE THEREOF AS EXCITATORY AMINO ACID AND GLYCINE RECEPTOR ANTAGONISTS | OREGON STATE (US) | 1996-02-28 | — | — | EP | claimed |
| EP-0688319-A1 | 4-HYDROXY-3-NITRO-1,2-DIHYDROQUINOLIN-2-ONES AND THE USE THEREOF AS EXCITATORY AMINO ACID AND GLYCINE RECEPTOR ANTAGONISTS | The STATE OF OREGON acting by and through the STATE BOARD OF HIGHER EDUCATION on behalf of the UNIV. OF OREGON (US) | 1995-12-27 | — | — | EP | claimed |
| WO-1994020470-A1 | 4-HYDROXY-3-NITRO-1,2-DIHYDROQUINOLIN-2-ONES AND THE USE THEREOF AS EXCITATORY AMINO ACID AND GLYCINE RECEPTOR ANTAGONISTS | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and onbehalf of THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE, OREGON (US) | 1994-09-15 | — | — | WO | claimed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7732146-B2 | Method for screening an agent that modulates activity of macrophage migration inhibitory factor | AVANIR PHARMACEUTICALS (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1389110-B1 | INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME | AVANIR PHARMACEUTICALS (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20100010217-A1 | METHODS FOR THE PREPARATION OF IMIDAZOLE-CONTAINING COMPOUNDS | NOVARTIS AG (CH) | 2010-01-14 | — | — | US | disclosed |
| US-7514225-B2 | Method for screening an agent that modulates activity of macrophage migration inhibitory factor | AVANIR PHARMACEUTICALS (US) | 2009-04-07 | — | — | US | disclosed |
| EP-2010530-A2 | METHODS FOR THE PREPARATION OF IMIDAZOLE-CONTAINING COMPOUNDS | Novartis AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-7435737-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTIALS (US) | 2008-10-14 | — | — | US | disclosed |
| US-4988815-A | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines | RIKER LABORATORIES, INC. (US) | 1991-01-29 | — | — | US | disclosed |
| EP-0385630-A2 | 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals | RIKER LABORATORIES, INC. (US) | 1990-09-05 | — | — | EP | disclosed |
| US-4192876-A | ANTIALLERGENS | SANDOZ, INC. (US) | 1980-03-11 | — | — | US | disclosed |
| US-4192876-A | ANTIALLERGENS | SANDOZ, INC. (US) | 1980-03-11 | — | — | US | disclosed |
| US-4192876-A | ANTIALLERGENS | SANDOZ, INC. (US) | 1980-03-11 | — | — | US | disclosed |
| US-4065457-A | ANTIBODY INHIBITORS | BEECHAM GROUP LIMITED (GB) | 1977-12-27 | — | — | US | disclosed |
| US-4065457-A | ANTIBODY INHIBITORS | BEECHAM GROUP LIMITED (GB) | 1977-12-27 | — | — | US | disclosed |
| US-3962445-A | Anti-allergenic carbostyril derivatives | BEECHAM GROUP LIMITED (EN) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010217-A1 | METHODS FOR THE PREPARATION OF IMIDAZOLE-CONTAINING COMPOUNDS | IDH3B, IDH3A, ABL1 | GRIN2D 3126/4885GRIN3B 1931/4885GRIN1 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.